Latest Investor Confidence News

Infini Resources has raised A$3 million through a flow-through share placement at a significant premium, fueling Phase 2 drilling at its Portland Creek Uranium Project in Canada. The capital raise underscores strong investor confidence ahead of a critical exploration push.

Perpetual Resources has raised $1.6 million to accelerate exploration of lithium and caesium deposits in Brazil, following promising initial drilling results at its Igrejinha project.

Macro Metals Limited has successfully raised A$2 million through a share placement, positioning itself to accelerate exploration and expand its mining services operations.

SRJ Technologies has secured $1.38 million from institutional investors in a fully underwritten entitlement offer, setting the stage for a strategic joint venture and acquisition in the Middle East. The company aims to raise an additional $1.15 million through a retail offer to support its growth ambitions.

Platinum Investment Management has officially terminated its Scheme Implementation Deed with Platinum Capital Limited, marking a significant shift in the management of the Platinum International Fund Complex ETF.

HeraMED Limited has resumed trading on the ASX following the release of its quarterly reports and a significant capital raising announcement, marking a pivotal moment for the medical device company.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Reckon Limited has delivered a robust half-year performance with a 16% revenue increase and a 29% rise in net profit attributable to members, while declaring a steady fully franked dividend. Despite these gains, the company’s net tangible assets per share remain negative, highlighting ongoing balance sheet pressures.

Leeuwin Metals Ltd has addressed a sudden spike in its share price and trading volume, confirming no undisclosed material information exists and attributing the movement to external market factors and a new research report.

Race Oncology’s Phase 1b/2 trial of RC110 bisantrene for relapsed or refractory acute myeloid leukemia has demonstrated a 40% response rate, exceeding expectations and offering new hope for difficult-to-treat patients.

Hudson Investment Group faces intense scrutiny from ASX after its auditor issued a Disclaimer of Opinion on the 2024 financial report, citing doubts over a $2.4 million property receivable and the company’s going concern status.

HeraMED Limited has raised $1.98 million through a discounted share placement to fund its digital maternity care platform's commercial growth across the US, Australia, and Europe.